NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$16.91
-1.08 (-6.00%)
Close of Nov 06, 2026 · end-of-day data
TNDM 8-K filings in 2026
Every material Form 8-K Tandem Diabetes Care filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tandem Diabetes Care reported third-quarter 2026 results for the period ended September 30, 2026, with worldwide sales up 14% to $283.7 million and a net loss of $7.1 million, compared with $21.2 million a year earlier. The company reaffirmed its full-year 2026 guidance, including sales of approximately $1.065 billion to $1.085 billion.
Worldwide sales rose 14% to $283.7 million; U.S. sales rose 9% to $191.0 million and international sales rose 26% to $92.6 million.
Gross margin was 57%, compared with 54% in the third quarter of 2025.
Operating loss was $2.4 million, compared with $22.9 million a year earlier; adjusted EBITDA was $18.0 million.
For 2026, the company reaffirmed sales guidance of $1.065 billion to $1.085 billion and adjusted EBITDA margin guidance of 5% to 6%.
Tandem Diabetes Care reported second quarter 2026 sales of $254.6 million, up 6% from $240.7 million a year earlier, with gross margin of 57% versus 52%. GAAP net loss narrowed to $21.2 million from $52.4 million, and the company reaffirmed its full-year 2026 sales guidance, which matters to shareholders because it shows revenue growth and lower losses while the company updated only its non-cash expense outlook.
Worldwide sales of $254.6 million, including $179.3 million in the U.S., up 5% in the U.S. and 7% internationally
GAAP net loss of $21.2 million, compared with $52.4 million in the second quarter 2025, which included a $20.0 million litigation settlement expense
Full-year 2026 sales guidance reaffirmed at approximately $1.065 billion to $1.085 billion
Non-cash charges guidance lowered to approximately $85 million from $100 million
At its May 20, 2026 annual meeting, Tandem Diabetes Care stockholders approved charter amendments that allow removal of directors with or without cause and limit officer liability, and approved a 3,260,000-share increase to the 2023 Long-Term Incentive Plan. The company filed the amended charter with Delaware on May 21, 2026, and all nine director nominees were elected, though director Christopher Twomey received 7,034,208 against votes, far more than other nominees.
Stockholders approved the Section 141(k) amendment allowing director removal with or without cause, with 57,818,029 for and 126,025 against.
Officer exculpation amendment passed with 45,926,405 for and 9,043,831 against.
The 2023 Long-Term Incentive Plan increase of 3,260,000 shares was approved with 53,846,696 for and 1,108,529 against.
Amended charter was filed with Delaware on May 21, 2026.
Tandem Diabetes Care said on May 11, 2026 that it notified Executive Vice President and Chief Commercial Officer Mark Novara that his employment is being terminated without cause, with his last day scheduled for May 18, 2026. The company said its strategy and 2026 goals remain unchanged, and the filing gives no successor or financial terms.
Mark Novara, EVP and Chief Commercial Officer, notified May 11, 2026
Termination is without cause; last day scheduled for May 18, 2026
Company states its strategy and 2026 goals remain unchanged
Tandem Diabetes Care reported first quarter 2026 sales of $247.2 million, up 5% from a year earlier, with gross margin rising to 55% from 51%. The company narrowed its net loss to $20.4 million, or $0.30 per share, from $130.6 million, or $1.97 per share, in the prior-year quarter, which included a $75.2 million acquired R&D charge. It reaffirmed its full-year 2026 financial guidance, including sales of $1.065 billion to $1.085 billion.
Worldwide sales rose 5% to $247.2 million; U.S. sales rose 7% to $160.8 million and international sales rose 3% to $86.4 million
Net loss was $20.4 million, or $0.30 per share, versus a net loss of $130.6 million, or $1.97 per share, in Q1 2025
Gross margin was 55%, compared with 51% a year earlier; adjusted EBITDA was $2.7 million, or 1% of sales
Company reaffirmed 2026 guidance for sales of approximately $1.065 billion to $1.085 billion
Tandem Diabetes Care completed a private offering of $300.0 million of 0.00% convertible senior notes due March 15, 2032, including a $35.0 million option exercised in full by the initial purchasers. The notes carry no regular interest and are convertible into cash, shares, or a combination, at the company's election, at an initial conversion price of about $36.99 per share. The company adds this debt to its balance sheet, and dilution from conversion is partly offset by capped call transactions subject to a cap.
$300.0 million principal, including the $35.0 million option exercised in full; notes mature March 15, 2032
Initial conversion price of about $36.99 per share, a premium of about 37.5% to the February 24, 2026 last reported sale price
Net proceeds of about $290.7 million after discounts and offering expenses; $15.3 million used to pay the cost of the capped call transactions
The company may not redeem the notes before March 20, 2029
Tandem Diabetes reported fourth-quarter and full-year 2025 results on February 19, 2026, and gave 2026 guidance. Worldwide sales rose 3% in the quarter to $290.4 million and 8% for the year to $1.015 billion, but the full-year GAAP net loss grew to $204.7 million from $96.0 million, including a $75.2 million acquired in-process research and development charge. The company expects 2026 sales of $1.065 billion to $1.085 billion, which would be above 2025 sales.
Q4 2025 GAAP operating income was $8.3 million, compared with an operating loss of $0.6 million a year earlier; Q4 net loss was $0.6 million versus net income of $0.8 million.
Full-year 2025 GAAP net loss was $204.7 million, or $3.04 per share, compared with $96.0 million, or $1.47 per share, in 2024.
2026 guidance: sales of $1.065 billion to $1.085 billion, gross margin of 56% to 57%, and adjusted EBITDA margin of 5% to 6%.
The company is moving to a pay-as-you-go model in the U.S. pharmacy channel, which the filing says creates a $70 million to $80 million headwind in 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tandem Diabetes Care filing is on SEC EDGAR ↗. 8-K briefs of other companies →